ArticleOpen forum infectious diseases2024

A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months.

Joanne M Langley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.